What Happens If Ketamine Therapy Doesn't Work? Next Steps Explained

Every responsible discussion of ketamine therapy must include an honest conversation about what happens when it does not work. The enthusiasm around ketamine's rapid antidepressant effects is well-earned -- it is a genuinely transformative treatment for many patients. But "many" is not "all," and patients deserve transparency about realistic expectations, what non-response looks like, and what options remain if ketamine is not the answer for them.

Setting Realistic Expectations

The clinical data on ketamine for treatment-resistant depression shows approximately 60 to 70 percent of patients experience a meaningful response. That is an impressive number, especially considering these patients have already failed to respond to multiple other treatments. But it also means that roughly 30 to 40 percent of patients do not achieve the improvement they hoped for.

This statistic deserves context. A 60 to 70 percent response rate is actually quite strong compared to other treatments for treatment-resistant depression. Traditional antidepressant switches have response rates of 10 to 30 percent after the first two medications have failed. Even interventions like TMS and ECT have response rates broadly similar to ketamine's.

The point is not that ketamine has a low success rate -- it does not. The point is that no treatment works for everyone, and having a plan for the possibility of non-response is a sign of good clinical care, not pessimism.

Defining "Not Working"

Before concluding that ketamine therapy has not worked, it is important to define what we mean. Non-response is not always clear-cut.

Complete non-response means no noticeable improvement in symptoms after an adequate trial -- typically four to six sessions. The depression feels unchanged in intensity, frequency, and impact on daily life. This is the clearest form of treatment failure.

Partial response is more common and more complicated. The patient notices some improvement -- perhaps better sleep, slightly more energy, or brief periods of lighter mood -- but the overall burden of depression remains significant. Partial response is not failure; it is information that the treatment is having an effect but may need optimization.

Initial response followed by relapse describes patients who feel substantially better after the first few sessions but find that improvement does not last. This pattern suggests the treatment is effective but the maintenance protocol needs adjustment.

Unrealistic expectations can also create the perception of non-response. If a patient expects complete elimination of depression after two sessions, they may feel the treatment "did not work" even though they are showing measurable improvement that would continue to build with additional sessions.

Your Tovani Health clinician uses standardized assessment tools to track your symptoms objectively, which helps distinguish genuine non-response from these other scenarios.

Dose and Protocol Adjustments

Before concluding that ketamine therapy has failed, several adjustments can be made:

Dose optimization. Starting doses are conservative by design. Some patients require higher doses to achieve therapeutic effects. If you have tolerated your current dose well but have not seen adequate improvement, a dose increase may be the next step. This is done gradually with careful monitoring according to our safety protocols.

Session frequency adjustment. Some patients respond better to more frequent initial sessions. If twice-weekly sessions have not produced adequate response, your clinician may recommend a brief period of more intensive treatment.

Route of administration changes. Sublingual absorption varies between patients depending on factors like oral pH, saliva volume, and technique. Your clinician may adjust instructions about how to optimize absorption -- for example, extending the time you hold the medication under your tongue.

Environmental optimization. The setting and preparation for each session can affect outcomes. If sessions have been disrupted by noise, stress, or inadequate preparation, optimizing these factors may improve response.

Addressing interfering factors. Certain medications, particularly benzodiazepines, can significantly blunt ketamine's therapeutic effects. Substance use, poor sleep, and high stress levels can also reduce response. Identifying and addressing these factors may unmask a treatment response that was being suppressed.

Understanding how ketamine works at a neurochemical level helps explain why these adjustments matter. The goal is to optimize the glutamate cascade and neuroplasticity window that drive therapeutic benefit.

What Predicts Non-Response?

Research has identified some factors that may be associated with lower response rates:

• Longer duration of current depressive episode. Depression that has persisted continuously for many years may be more resistant to ketamine therapy.
• Active substance use disorders. Ongoing heavy alcohol or drug use can interfere with treatment response.
• Certain medication combinations. As mentioned, benzodiazepines and some other medications may reduce ketamine's effectiveness.
• Personality disorder comorbidity. Some personality disorder patterns may complicate treatment response.
• Chronic inflammation. Emerging research suggests that patients with high levels of systemic inflammation may respond less robustly to ketamine.

None of these factors are absolute predictors. Some patients with every risk factor respond well, and some patients with no risk factors do not. But they provide a framework for understanding non-response and may guide alternative treatment selection.

Alternative Treatments to Consider

If ketamine therapy has not provided adequate relief after a thorough trial with appropriate adjustments, several evidence-based alternatives merit consideration:

Transcranial magnetic stimulation (TMS). TMS works through a completely different mechanism than ketamine -- electromagnetic brain stimulation rather than pharmacology. Patients who do not respond to ketamine may respond to TMS and vice versa, because they target different aspects of depression neurobiology.

Electroconvulsive therapy (ECT). ECT remains the most effective treatment for severe, treatment-resistant depression, with response rates of 50 to 70 percent even in patients who have failed multiple other interventions. Modern ECT is significantly different from its historical reputation, with refined techniques that minimize side effects.

Medication optimization. A psychiatric medication specialist may identify combinations, augmentation strategies, or novel agents that have not been tried. Lithium augmentation, thyroid hormone supplementation, and newer antidepressants with unique mechanisms are all possibilities.

Intensive psychotherapy. For some patients, the primary driver of depression is psychological rather than purely neurochemical. Intensive evidence-based psychotherapy -- particularly cognitive behavioral therapy, dialectical behavior therapy, or EMDR for trauma-related depression -- can be effective when medications alone are not.

Lifestyle medicine. Regular vigorous exercise, sleep optimization, dietary changes (particularly anti-inflammatory diets), and stress reduction techniques have genuine evidence for depression management. While these are often recommended as complements to other treatment, they can be powerful interventions in their own right.

Clinical trials. If you have treatment-resistant depression that has not responded to multiple evidence-based interventions, you may be a candidate for clinical trials studying new treatments. Your clinician can help you identify trials that might be appropriate.

The Importance of Not Giving Up

I want to address something that patients who have experienced multiple treatment failures feel deeply: hopelessness about ever finding something that works. This is understandable. Each failed treatment can feel like evidence that recovery is impossible.

But the evidence strongly suggests otherwise. The vast majority of patients with treatment-resistant depression eventually find a treatment or combination of treatments that provides meaningful relief. The path may be longer and more frustrating than anyone would choose, but the outcome -- genuine improvement in quality of life -- is achievable.

Every treatment you try provides information. A medication that does not work rules out one mechanism and points toward others. A therapy that partially helps identifies what aspects of your depression are most amenable to treatment. Non-response to ketamine does not mean non-response to everything -- it means one pathway has been explored and the search continues with better information.

Our Commitment to You

At Tovani Health, we do not view non-response as a patient failure or a treatment failure. We view it as clinical information that guides the next step. If ketamine therapy does not produce the results we both hoped for, your clinician will have an honest conversation about what we learned, what adjustments might help, and what alternatives to consider.

We also do not believe in continuing a treatment indefinitely without evidence of benefit. If after an adequate trial and appropriate adjustments you are not improving, we will tell you directly and help you identify the most promising next option.

Starting the Process

Whether ketamine therapy ends up being your solution or one step in an ongoing search for the right treatment, the evaluation process provides valuable clinical information. Understanding your specific depression profile, treatment history, and medical background helps guide decisions regardless of which treatment ultimately works best.

Check your eligibility for ketamine therapy with Tovani Health. Our approach is thorough, honest, and committed to helping you find effective treatment -- whether that turns out to be ketamine or something else.